TheraRadar
Data updated: Jun 28, 2026

CLINDAMYCIN PHOSPHATE AND TRETINOIN (clindamycin phosphate) · SOLARIS PHARMA CORP

Dermatology Approved 2015-06-12

Clindamycin phosphate and tretinoin gel 1.2% / 0.025% is indicated for the topical treatment of acne vulgaris in patients 12 years or older.

Source: FDA Label
3
Indications
--
Phase 3 Trials
11
Years on Market

Details

Status
Prescription
First Approved
2015-06-12
Routes
TOPICAL
Dosage Forms
GEL

CLINDAMYCIN PHOSPHATE AND TRETINOIN Approval History

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
3 FDA actions from 2015 to 2023
Sep 2023 ORIGINAL
Update
Feb 2022 ORIGINAL
Update
Jun 2015 ORIGINAL
Update

What CLINDAMYCIN PHOSPHATE AND TRETINOIN Treats

1 indications

CLINDAMYCIN PHOSPHATE AND TRETINOIN is approved for 1 conditions since its original approval in 2015. These indications span multiple therapeutic areas including oncology, immunology, and more.

Source: FDA Label

CLINDAMYCIN PHOSPHATE AND TRETINOIN Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to CLINDAMYCIN PHOSPHATE AND TRETINOIN

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ACANYA
BENZOYL PEROXIDE
1 shared
BAUSCH
Shared indications:
ACZONE
DAPSONE
1 shared
ALMIRALL
Shared indications:
ADAPALENE AND BENZOYL PEROXIDE
ADAPALENE
1 shared
SUN PHARMA CANADA
Shared indications:
📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT04469075 19-342 Ph 2 active not recruiting Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields
NCT04321070 CLPL 1907 Ph 1 completed Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
NCT00616330 CBC-302-602-622467 Ph 3 completed Vaginal Infection Study
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CLINDAMYCIN PHOSPHATE AND TRETINOIN FDA Label Details

Indications & Usage

Clindamycin phosphate and tretinoin gel 1.2% / 0.025% is indicated for the topical treatment of acne vulgaris in patients 12 years or older. Clindamycin phosphate and tretinoin gel 1.2% / 0.025% is a lincosamide antibiotic and retinoid combination product indicated for the topical treatment of acne vulgaris in patients 12 years or older.

Track CLINDAMYCIN PHOSPHATE AND TRETINOIN with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.